PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.

Br J Cancer · 2011 · PMC3049593 · PMID 21285983

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

However, it is not clear why 40 mg kg −1 once-weekly failed to reach significance but interestingly sorafenib demonstrated no effect on metastasis in this model.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.